Ascelia Pharma AB (publ) (STO:ACE)

Market Cap	402.17M
Revenue (ttm)	n/a
Net Income (ttm)	-88.72M
Shares Out	126.87M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	79.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,335,721
Average Volume	797,608
Open	3.170
Previous Close	3.170
Day's Range	2.860 - 3.240
52-Week Range	2.305 - 5.230
Beta	0.95
RSI	53.44
Earnings Date	Feb 5, 2026

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headq...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACE